Currently, all the major guidelines support prescribing SGLT2 inhibitors, besides T2DM patients, for patients with heart failure regardless of ejection fraction (class of recommendation: I, level of evidence A), and for patients with CKD regardless of the presence of diabetes mellitus (class of recommendation: I, level of evidence A) [22,23]. This evidence concerns the gene SLC5A2 and heart failure.